CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain

Behavioural Pharmacology

Volumn 22, Issue 5-6, 2011, Pages 607-616

  Khasabova, Iryna A ^a   Gielissen, James ^c   Chandiramani, Anisha ^a   Harding Rose, Catherine ^a   Odeh, Desiree Abu ^b   Simone, Donald A ^a,c   Seybold, Virginia S ^b,c  

^a School of Dentistry   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

cancer; cannabinoid; hyperalgesia; mouse

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ARACHIDONYLCYCLOPROPYLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; MORPHINE; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CANCER PAIN; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; HYPERALGESIA; INJECTION SITE; MALE; MOUSE; NONHUMAN;

ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HYPERALGESIA; MALE; MICE; MICE, INBRED C3H; MORPHINE; NEOPLASMS, EXPERIMENTAL; PAIN; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 80051919321     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283474a6d     Document Type: Article

References (51)

1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. (2007). Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptor. Nat Neurosci 10:870-879. (Pubitemid 47013432)
2. Anand P, Whiteside G, Fowler CJ, Hohmann AG (2009). Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 60:255-266.
3. Backonja M-M, Stacey B (2004). Neuropathic pain symptoms relative to overall pain rating. J Pain 5:491-497. (Pubitemid 39535205)
4. Cain DM, Wacnik PW,Turner M,Wendelschafer-Crabb G, Kennedy WR,Wilcox GL, Simone DA (2001). Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci 21:9367-9376. (Pubitemid 33096880)
5. Casanova ML, Blázquez C, Martínez-Palacio J,Villanueva C, Fernández-Aceñero MJ, Huffman JW, et al. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111:43-50. (Pubitemid 36134847)
6. Coleman RE (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s-6249s. (Pubitemid 44703797)
7. Curto-Reyes V, Llames S, Hidalgo A, Menéndez L, Baamonde A (2010). Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 160:561-573.
8. Desroches J, Guindon J, Lambert C, Beaulieu P (2008). Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 155:913-924.
9. Fairbanks CA, Nguyen HO, Grocholski BM, Wilcox GL (2000). Moxonidine, a selective imidazoline-alpha2-adrenergic receptor agonist, produces spinal synergistic antihyperalgesia with morphine in nerve-injured mice. Anesthesiol 93:765-773.
10. Fox A, Bevan S (2005). Therapeutic potential of cannabinoind receptor agonists an analgesic agesnt. Expert Opin Investig Drugs 14:695-703. (Pubitemid 40895195)
11. Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G; on behalf of the Writing Protocol Committee and the Cancer Pain Outcome Research Study Group (CPOR SG) Investigators (2010). Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain 2011. [Epub ahead of print]
12. Guerrero AV, Quang P, Dekker N, Jordan RCK, Schmidt BL (2008). Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett 422:77-81.
13. Guindon J, Hohmann AG (2008). Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153:319-334.
14. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG (2007). Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 150:153-163. (Pubitemid 46160605)
15. Hald A, Ding M, Egerod K, Hansen RR, Konradsen D, Jørgensen SG, et al. (2008). Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Pharmacol Biochem Behav 91:38-46.
16. Hamamoto DT, Giridharagopalan S, Simone DA (2007). Acute and chronic administration of the cannabinoid receptor agonist CP 55 940 attenuates tumor-evoked hyperalgesia. Eur J Pharmacol 558:73-87. (Pubitemid 46328873)
17. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. (1999). HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96:14228-14233. (Pubitemid 30000633)
18. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, et al. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289: 1427-1433. (Pubitemid 29246674)
19. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108-1112. (Pubitemid 40910518)
20. Honore P, Rogers SD, Schwei MJ, Salak-Johnson JL, Luger NM, Sabino MC, et al. (2000). Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98:585-598. (Pubitemid 30408178)
21. Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, et al. (2010). Central and peripheral sites of action for CB(2) receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 2011. [Epub ahead of print]
22. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. (2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102:3093-3098. (Pubitemid 40299921)
23. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, et al. (2006). CB2 cannabinoid receptor mediation of antinociception. Pain 122:36-42.
24. Khasabova IA, Stucky CL, Harding-Rose C, Eikmeier L, Beitz AJ, Coicou LG, et al. (2007). Chemical interactions between fibrosarcoma cancer cells and sensory neurons contribute to cancer pain. J Neurosci 27:10289-10298. (Pubitemid 47450473)
25. Khasabova IA, Khasabov SG, Harding-Rose C, Coicou LG, Seybold BA, Lindberg AE, et al. (2008). A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 28:11141-11152.
26. Koizumi S, Fujishita K, Inoue K, Shigemoto-Mogami Y, Tsuda M, Inoue K (2004). Ca2 + waves in keratinocytes are transmitted to sensory neurons: the involvement of extracellular ATP and P2Y2 receptor activation. Biochem J 380:329-338. (Pubitemid 38788103)
27. Lan R, Gatley J, Lu Q, Fan P, Fernando SR, Volkow ND, et al. (1999). Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci 1:E4.
28. Leichsenring A, Andriske M, Bäcker I, Stichel CC, Lübbert H (2009). Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol 379:627-636.
29. Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, et al. (2010). A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci 86:646-653.
30. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, et al. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93:239-245. (Pubitemid 32763181)
31. Mancini I, Dumon JC, Body JJ (2004). Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22:3587-3592. (Pubitemid 41103666)
32. Marriott KS, Huffman JW (2008). Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr Top Med Chem 8:187-204. (Pubitemid 351795769)
33. Matsuda LA, Lolait SJ, Brownstein MJ, Young CA, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
34. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65. (Pubitemid 23305569)
35. Oka S, Wakui J, Ikeda S, Yanagimoto S, Kishimoto S, Gokoh M, et al. (2006). Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. J Immunol 177:8796-8805. (Pubitemid 44893846)
36. Pertwee RG (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156:397-411.
37. Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C, Bifulco M (2009). Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab 23:117-131.
38. Portenoy RK (1989). Cancer pain: epidemiology and syndromes. Cancer 63:2298-2307.
39. Portenoy RK (1999). Managing cancer pain poorly responsive to systemic opioid therapy. Oncology (Williston Park) 13:25-29. (Pubitemid 29242246)
40. Potenzieri C, Harding-Rose C, Simone DA (2008). The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 1215:69-75.
41. Quartilho A, Mata HP, Ibrahim MM,Vanderah TW, Porreca F, Makriyannis A, Malan TP Jr (2003). Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99:955-960. (Pubitemid 37186088)
42. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126:665-672. (Pubitemid 29087845)
43. Schweizerhof M, Stösser S, Kurejova M, Njoo C, Gangadharan V, Agarwal N, et al. (2009). Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med 15:802-807.
44. Tallarida RJ (1992). Statistical analysis of drug combinations for synergism. Pain 49:93-97.
45. van den Beuken-van Everdingen MH, De Rijke JM, Kessels AG, Schouten HC, Van Kleef M, Patijn J (2007). High prevalence of pain in patients with cancer in a large population-based study in the Netherlands. Pain 132:312-320. (Pubitemid 350051568)
46. Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML, Walcheck BK, Beitz AJ, Wilcox GL (2001). Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 21:9355-9366. (Pubitemid 33096879)
47. Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, et al. (2005). A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol 528:65-72. (Pubitemid 41773653)
48. Yamamoto J, Kawamata T, Niiyama Y, Omote K, Namiki A (2008a). Down-regulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 151:843-853.
49. Yamamoto W, Mikami T, Iwamura H (2008b). Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 583:56-61.
50. Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV, et al. (2008). In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 153:390-401.
51. Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, et al. (2009). Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-di- methyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 328:141-151.